Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Demonstrating the principal mechanism of action of medical devices intended for vaginal use on reconstructed human vaginal epithelium: the case of two hyaluronic acid-containing devices.

Frontiers in drug safety and regulation·2025

Same author

Stiripentol prevents lethal audiogenic seizures in two mouse strains, relevant for SUDEP prevention.

Epilepsy & behavior : E&B·2025

Same author

Treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem.

Scientific reports·2024

Same author

An Update on Stiripentol Mechanisms of Action: A Narrative Review.

Advances in therapy·2024

Same author

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models.

Cancers·2023

Same author

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models.

International journal of molecular sciences·2022

Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026

Same journal

T Cell subsets for therapy-unconventional CD1d-restricted natural killer T cells.

Advances in pharmacology (San Diego, Calif.)·2026

Same journal

Tracking therapeutic T cells in vivo.

Advances in pharmacology (San Diego, Calif.)·2026

Same journal

In vivo transduction of CAR T cells: Pharmacological principles, delivery platforms, and the road to clinical translation.

Advances in pharmacology (San Diego, Calif.)·2026

Same journal

Transient T cell therapies.

Advances in pharmacology (San Diego, Calif.)·2026

Same journal

Manufacturing as biology: How T-cell processing shapes therapeutic outcomes.

Advances in pharmacology (San Diego, Calif.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Developing a Behavioral Box for Assessing Prepulse Inhibition and Neural Activity in Psychiatric Animal Models

Developing a Behavioral Box for Assessing Prepulse Inhibition and Neural Activity in Psychiatric Animal Models

Published on: July 22, 2025

Preclinical behavioral models for predicting antipsychotic activity.

Vincent Castagné¹, Paul C Moser, Roger D Porsolt

¹Porsolt & Partners Pharmacology, 9 Bis Rue Henri Martin, 92100 Boulogne-Billancourt, France.

Advances in Pharmacology (San Diego, Calif.)

|March 17, 2010

Summary

This summary is machine-generated.

This review examines animal models for predicting antipsychotic drug efficacy against schizophrenia symptoms and their potential for causing extrapyramidal symptoms (EPS). It covers models for positive, negative, and cognitive domains, plus EPS liability assessments.

More Related Videos

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Strategies for Assessing Autistic-Like Behaviors in Mice

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

Related Experiment Videos

Last Updated: Jun 15, 2026

Developing a Behavioral Box for Assessing Prepulse Inhibition and Neural Activity in Psychiatric Animal Models

Developing a Behavioral Box for Assessing Prepulse Inhibition and Neural Activity in Psychiatric Animal Models

Published on: July 22, 2025

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Strategies for Assessing Autistic-Like Behaviors in Mice

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

Area of Science:

Neuroscience
Pharmacology
Psychiatry

Background:

Schizophrenia presents positive, negative, and cognitive symptoms.
Antipsychotic medications can cause extrapyramidal symptoms (EPS).
Clozapine's broad efficacy and lower EPS liability spurred research for similar agents.

Purpose of the Study:

To review animal behavioral procedures for predicting antipsychotic efficacy.
To assess animal models for predicting EPS liability.
To guide the development of novel antipsychotics with improved profiles.

Main Methods:

Rodent models for positive symptoms (dopamine, serotonin, glutamate systems).
Rodent models for negative symptoms (anhedonia, affective flattening, social interaction).
Rodent models for cognitive deficits (attention, learning, memory).
Animal models for EPS (parkinsonism, dystonia, akathisia, tardive dyskinesia).

Main Results:

Established rodent models exist for key schizophrenia symptom domains.
Various animal procedures can assess EPS liability.
The conditioned avoidance response (CAR) relevance is discussed.

Conclusions:

Animal models are crucial for evaluating antipsychotic drug candidates.
These models aid in predicting clinical efficacy and side effect profiles.
Further refinement of these models is essential for advancing schizophrenia treatment.